Unjoni Ewropea - Malti - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - spondylolisthesis - drogi għat-trattament ta 'mard tal-għadam - opgenra huwa indikat għal fużjoni spinali laterali posterolaterali f'pazjenti adulti bi spondylolistshes fejn l-awtograft naqas jew huwa kontra-indikat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - antithrombin alfa - defiċjenza ta 'antithrombin iii - aġenti antitrombotiċi - atryn huwa indikat għall-profilassi ta 'tromboemboliżmu fil-vini fil-kirurġija ta' pazjenti b'defiċjenza konġenitali ta 'antithrombin. atryn normalment jingħata flimkien ma 'eparina jew eparina b'piż molekulari baxx.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

opk biotech netherlands bv - emoglobina glutamer-200 (bovini) - sostituti tad-demm u l-perfuŻjoni soluzzjonijiet - klieb - oxyglobin jipprovdi appoġġ li jġorr l-ossiġenu lill-klieb li jtejbu s-sinjali kliniċi ta 'anemija għal mill-inqas 24 siegħa, indipendentement mill-kundizzjoni sottostanti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - fratturi tibjali - mediċini għall-kura ta'mard fl-għadam, proteini morfoġenetiċi ta ' għadam - trattament ta 'nonunion ta' tibja ta 'mill-inqas tul ta' 9 xhur, sekondarju għal trawma, f'pazjenti skeletriċi maturi, f'każijiet fejn trattament preċedenti b'autograft ikun falla jew l-użu ta 'autograft ma jkunx fattibbli.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - marda ta 'parkinson - mediċini kontra l-parkinson - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslicarbazepine acetate - epilessija - anti-epilettiċi, - zebinix huwa indikat bħala terapija adjunctive fl-adulti, adolixxenti u tfal b ' età hawn fuq 6 snin, ma b'sekwestru parzjali-iskoppjar bi jew mingħajr ġeneralizzazzjoni sekondarja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid - diabetes mellitus, tip 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku:bħala monoterapija f'pazjenti li għalihom l-użu ta' metformin huwa kkunsidrat xieraq minħabba 'intolleranza jew ta' kontra-indikazzjonijiet. barra minn hekk oħra prodotti mediċinali għall-kura tad-dijabete.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaċċini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - sustanzi kontra l-emorraġija - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bial - portela cª, s.a. - opicapone - marda ta 'parkinson - mediċini kontra l-parkinson - ongentys huwa indikat bħala terapija adjunctive għall-preparazzjonijiet ta ' ticlopidine hydrochloride / dopa decarboxylase inibituri (ddci) fil-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur li ma tistax tiġi stabilizzata fuq dawk l-għaqdiet. ongentys huwa indikat bħala terapija adjunctive għall-preparazzjonijiet ta ' ticlopidine hydrochloride / dopa decarboxylase inibituri (ddci) fil-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur li ma tistax tiġi stabilizzata fuq dawk l-għaqdiet.